BANF1 and acute myeloid leukemia: BAF complex ATPase inhibitors (BRM011, BRM014, and BRM017) have shown promise for AML therapy, including induced differentiation of independent leukemic cell populations, but with notable off-target effects—likely due to the essential role of BAF in typical hematopoiesis (8, 65).